Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Previse
AddedFeb 15, 2024
UpdatedJun 18, 2026
Previse

Previse

Seed

Previse: Pioneering early cancer detection through affordable, accurate biomarker technology, starting with esophageal cancer.

HQ
Baltimore, MD, US
Founded
2018
Overview
Compare
Fundraising
Employees
Website

Previse was founded with the core mission of saving lives through the earlier detection and prevention of cancer, beginning with esophageal cancer. The company leverages decades of research from the GI Early Detection Biomarker Lab and funding from the National Institutes of Health (NIH) to develop its technology. Previse offers Esopredict™, a molecular test that provides personalized guidance for Barrett’s esophagus surveillance and treatment decisions. Their focus is on utilizing biomarker technology to give patients and healthcare providers timely and accurate information.

Notable affiliated individuals include researchers from the GI Early Detection Biomarker Lab, whose work underpins Previse's technology. The company's key achievements include securing NIH grants and developing a market-ready product, Esopredict™, which is available through licensed healthcare providers. Previse's impact lies in its potential to significantly improve cancer outcomes by enabling earlier detection and more precise treatment strategies, thereby addressing a critical need in oncology diagnostics.

Previse - Quick Facts

When was Previse founded?

Previse was founded in 2018.

Where is Previse's headquarters located?

Previse's headquarters is located in Baltimore, MD, US.

When was Previse's last funding round?

Previse's most recent funding round was for $1.8M (USD) in October 2023.

How much has Previse raised to-date?

As of Oct 11, 2023, Previse has raised a total of $6.3M (USD).

How many employees does Previse have?

Previse has 12 employees as of Feb 4, 2024.

Previse - Classification

Ownership
  • Private
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Recurring
  • Software
Customer
  • Consumers
  • Enterprise
Main Product
  • Biomarker Testing
Tags
  • Data Information
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 9 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 620000Health Care and Social Assistance
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 7372Prepackaged Software
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified